Your session is about to expire
← Back to Search
Anti-CD137 + Anti-CTLA-4 Monoclonal Antibodies for Advanced Cancer
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective. The drug will be given to people with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a transplant of tissue or an organ from another person, except for a cornea transplant.I am not legally allowed to make my own decisions.I have not been in a clinical trial for a new treatment or device within the last 3 weeks.There is evidence of a measurable disease seen on imaging scans that doctors will use a specific system to evaluate.I have or had brain tumors/metastases but they are now stable, and any related symptoms or treatments have been resolved.I won't need any other cancer treatments while in this study.I do not have serious heart conditions or recent major heart or stroke events.I have HIV with a low CD4 count and am not on stable HIV treatment.I am not on any immune-suppressing drugs, except for low-dose steroids or inhaled/topical steroids.I had cancer before, but I finished treatment over 2 years ago and am now cancer-free.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.I agree to use effective birth control during and up to 90 days after the study.You have a mental health or substance abuse disorder that may make it difficult for you to follow the study requirements.I have completed my COVID-19 vaccination series more than 7 days ago.My kidney function is within the required range.I have lasting side effects from past treatments, but not severe nerve issues or hair loss.I have not had severe allergic reactions to certain medications, long-term steroid treatments, serious lung conditions, uncontrolled asthma, or pneumonitis treated with steroids.My blood counts meet the required levels without recent transfusions.I am not pregnant and cannot become pregnant due to age, surgery, or menopause.I have not had recent cancer treatments outside the allowed time before starting the study drug.I am expected to live more than 3 months and can care for myself with minimal assistance.I agree to participate in the study and have signed the consent form.My cancer is advanced or has spread, and standard treatments have failed or are not available.I can provide a recent tumor sample not from an irradiated area and agree to a biopsy during the study if needed.My liver is functioning well according to recent tests.I am using or willing to use effective birth control or practice abstinence.I am 18 years old or older.Your blood clotting levels are within a safe range, unless you are already taking medication to thin your blood.I am currently being treated for an infection.I have had anti-CD137 therapy and the study sponsor agrees I can join.
- Group 1: Combination Therapy with 3-week AGEN2373 in combination with 6-week Botensilimab
- Group 2: Combination Therapy with 3-week AGEN2373 Monotherapy Lead-In Combination with 6-week Botensilimab
- Group 3: 3-Week Monotherapy with AGEN2373
- Group 4: 4-Week Monotherapy with AGEN2373
- Group 5: 2-Week Monotherapy with AGEN2373
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What implications does AGEN2373 have on the wellbeing of individuals?
"With only limited data on efficacy and safety, AGEN2373 scored a 1 in terms of risk levels."
Has a similar trial ever been conducted before?
"Currently, 6 clinical trials revolving around AGEN2373 are ongoing in 8 nations and 95 cities. The initial experiment for this drug was launched by Agenus Inc., back in 2019; it included 195 patients and finished its Phase 1 assessment stage with success. Two other studies have since been completed."
How many participants are enrolled in this clinical investigation?
"This clinical trial necessitates 200 qualified candidates. Agenus Inc., the sponsor, is managing the study from a handful of sites such as Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas and University of Southern California Norris Comprehensive Cancer Centre in Los Angeles."
How many venues are offering this trial to participants?
"Currently, 13 clinical trial sites are available for this study; three of which can be found in Dallas, Los Angeles, and Seattle. Therefore it is recommended to choose a facility close by to minimise travel requirements if you decide to participate."
Has AGEN2373 been tested experimentally in any other scientific investigations?
"Research on AGEN2373 began at Columbia University Irving Medical Center in 2019. There are currently two finished trials, and six more actively recruiting through multiple sites located primarily in Dallas, Texas."
What progress is this clinical trial aiming to make?
"According to the research funder, Agenus Inc., this trial will measure Dosage Limiting Toxicity (DLT) from Screening up to 90 days after final dose. Secondary variables of interest are Area under Plasma Concentration-Time Curve (AUC), Clearance Rate (CL), and Immunogenicity (ADA Profile)."
Are there presently any vacancies in this clinical research study?
"Affirmative. Clinicaltrials.gov reveals that applications are currently being accepted for this study, which was initiated on September 26th 2019 and recently revised on August 12th 2022. The trial is looking to recruit 200 individuals from 13 different clinics."
Share this study with friends
Copy Link
Messenger